The DFMO clinical trial is offering hope to children with hard to treat relapsed neuroblastoma. It is developed from research done at the children's cancer institute, it runs across 16 hospitals in Australia and the US.
DFMO drug acts by blocking the production of a molecule that is required for cells to grow and proliferate.
Researchers have shown that neuroblastoma cells are extremely sensitive to the action of DFMO and that when it is used in combination with other drugs, it blocks the growth and progression of tumour cells. This is because the molecules DFMO targets play a critical role in the development of neuroblastoma.
A child with high risk neuroblastoma who relapses after initial treatment has less than a 20% chance of survival.
The likelihood of Emily relapsing after over a year and a half of treatment is 70%!
- Liam Doyle
- Lisa Kennedy
- Lorraine Costigan
#1 fundraising platform
More people start fundraisers on GoFundMe than on any other platform. Learn more
In the rare case something isn’t right, we will work with you to determine if misuse occurred. Learn more
Expert advice, 24/7
Contact us with your questions and we’ll answer, day or night. Learn more